A drug‐repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6‐thioguanine as an effective therapeutic agent for TPMT‐low cancer cells. This evidence concerns the gene TPMT and pancreatic ductal adenocarcinoma.